Catalyst Pharmaceuticals ... (CPRX)
NASDAQ: CPRX
· Real-Time Price · USD
24.32
0.03 (0.12%)
At close: May 01, 2025, 3:59 PM
23.78
-2.24%
After-hours: May 01, 2025, 07:47 PM EDT
Catalyst Pharmaceuticals Revenue Breakdown
| Period Ending | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| License And Other Revenue Revenue | 2.27M | 68K | 1.46M | 71K | 105K | 62K | 74K | 71K | 64K | 56K | 38.27M |
| License And Other Revenue Revenue Growth | +3239.71% | -95.36% | +1961.97% | -32.38% | +69.35% | -16.22% | +4.23% | +10.94% | +14.29% | -99.85% | n/a |
| Product Revenue Net Revenue | 126.42M | 98.44M | 109.1M | 102.62M | 99.48M | 85.3M | 60.68M | 57.17M | 53.05M | 43.03M | n/a |
| Product Revenue Net Revenue Growth | +28.43% | -9.77% | +6.32% | +3.16% | +16.61% | +40.57% | +6.14% | +7.77% | +23.28% | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2020 |
|---|---|
| Canada Revenue | 33K |
| Canada Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 45.88M | 40.73M | 46.94M | 42.04M | 33.56M | 28.4M | 29.72M | 14.67M | 13.65M | 12.92M | 16.43M | 13.23M | 12.15M | 11.53M | 12.72M | 13.35M | 9.98M | 10.83M | 10.06M | 11.41M | 8.07M | 8.99M | 8.42M | 6.93M | 3.64M | 2.63M | 2.67M | 2.11M | 1.6M | 1.73M | 1.87M | 1.49M | 1.42M | 2.31M | 2.69M | 2.36M | 1.97M | 2.32M | 1.94M |
| Selling, General, and Administrative Revenue Growth | +12.64% | -13.23% | +11.66% | +25.26% | +18.19% | -4.45% | +102.60% | +7.47% | +5.66% | -21.38% | +24.22% | +8.84% | +5.39% | -9.31% | -4.77% | +33.72% | -7.83% | +7.65% | -11.80% | +41.42% | -10.24% | +6.79% | +21.51% | +90.06% | +38.51% | -1.62% | +26.92% | +31.55% | -7.39% | -7.31% | +24.93% | +5.18% | -38.41% | -14.33% | +14.03% | +19.51% | -14.87% | +19.43% | n/a |
| Research and Development Revenue | 3.28M | 2.98M | 2.58M | 1.97M | 83.66M | 3.95M | 3.56M | 4.09M | 8.31M | 3.98M | 3.4M | 4.99M | 4.49M | 4.45M | 3.01M | 4.18M | 3.75M | 4.35M | 4.22M | 6.31M | 4.6M | 4.63M | 3.31M | 8.42M | 4.54M | 3.7M | 3.26M | 3.4M | 2.7M | 2.45M | 2.81M | 2.82M | 2.49M | 2.51M | 3.55M | 3.83M | 3.04M | 2.58M | 2.35M |
| Research and Development Revenue Growth | +10.02% | +15.65% | +30.88% | -97.64% | +2015.88% | +11.01% | -12.97% | -50.75% | +108.64% | +17.04% | -31.83% | +11.25% | +0.83% | +47.99% | -27.98% | +11.36% | -13.80% | +3.00% | -33.06% | +37.23% | -0.70% | +39.95% | -60.70% | +85.46% | +22.50% | +13.68% | -4.28% | +25.87% | +10.33% | -12.87% | -0.24% | +13.10% | -0.59% | -29.25% | -7.44% | +25.93% | +18.05% | +9.70% | n/a |
| Sales and Marketing Revenue | 29.11M | 26.25M | 25.32M | 28.93M | 21.68M | 18.31M | 17.76M | 7.83M | 7.58M | 7.27M | 6.79M | 7.97M | 6.52M | 5.98M | 5.68M | 6.56M | 5.58M | 5.62M | 5.8M | n/a | 4.67M | 4.88M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sales and Marketing Revenue Growth | +10.89% | +3.66% | -12.48% | +33.44% | +18.40% | +3.08% | +126.96% | +3.20% | +4.35% | +7.04% | -14.85% | +22.28% | +9.03% | +5.37% | -13.51% | +17.64% | -0.77% | -3.14% | n/a | -100.00% | -4.31% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |